Arcus Biosciences, Inc. (RCUS)

29.57 -0.56 (-1.86%) USD  |  NYSE  |  Sep 04, 09:54
More

Arcus Biosciences Research and Development Expense (Annual) : 523.00M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for RCUS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 2016. Start Trial.
Date Value
December 31, 2025 523.00M
December 31, 2024 448.00M
December 31, 2023 340.00M
December 31, 2022 288.00M
December 31, 2021 256.35M
Date Value
December 31, 2020 159.35M
December 31, 2019 78.48M
December 31, 2018 49.65M
December 31, 2017 47.22M
December 31, 2016 14.25M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Halozyme Therapeutics, Inc. 81.49M
AVITA Medical, Inc. 20.84M
Iovance Biotherapeutics, Inc. 300.27M
Editas Medicine, Inc. 84.68M
Recursion Pharmaceuticals, Inc. 425.27M